Basel (Switzerland) and Mannheim (Germany), January 30, 2020 – VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, announced today that the Company will participate in several industry events in the coming months. Company representatives will be available for networking and one-on-one meetings at the following conferences:
BIO CEO & Investor Conference
February 10-11, 2020
New York, NY, USA
VAXIMM representatives will be available for one-on-one meetings during the conference. To schedule a meeting, please use the event partnering system or contact info@vaximm.com.
13th SACHS Annual European Life Science CEO Forum
February 19-20, 2020
Zurich, Switzerland
Dr. Heinz Lubenau, CEO, will give a corporate presentation on February 19th at 2:15 pm CET and participate in the panel, “Oncology Advanced Therapies & Diagnostics,” taking place on the same day at 4:30 pm. The Company will also host one-on-one meetings at this event. To request a meeting with VAXIMM, please sign up through the event’s meeting system.
14th Annual International Partnering Conference BIO-Europe Spring®
March 23-25, 2020
Paris, France
VAXIMM plans to give a corporate presentation and host one-on-one meetings at this event. To request a meeting, please sign up through the event’s partneringONE meeting system.
30th MedTech Investing Europe Conference
March 31-April 1, 2020
Lausanne, Switzerland
VAXIMM representatives will be available for one-on-one meetings during the conference. Dr. Heinz Lubenau also plans to give a corporate presentation. To schedule a meeting, please contact info@vaximm.com.
About VAXIMM
VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor. The Company has a pipeline of complementary development candidates targeting different tumor structures. Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including brain cancer. As part of a scientific collaboration with Merck KGaA and Pfizer Inc., VAXIMM has an ongoing clinical trial evaluating VXM01 in combination with the human anti-PD-L1 antibody, avelumab.
VAXIMM also has a neoantigen program currently in preclinical development; the Company’s platform allows for fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches. VAXIMM has a strategic clinical trial collaboration with NEC Corporation for the development of personalized neoantigen cancer vaccines. VAXIMM also has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs. VAXIMM’s investors include: BB Biotech Ventures, BioMed Partners, CMS, M Ventures, NEC and Sunstone Capital. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities. For more information, please see www.vaximm.com.
Contact:
VAXIMM AG
Dr. Heinz Lubenau
Phone: +49 621 8359 687 0
Email: info@vaximm.com
Media Inquiries:
MC Services AG
Katja Arnold, Laurie Doyle
Phone: +49 89 210228 0
Email: vaximm@mc-services.eu
